Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,113.23
(
-0.36%
)
US TECH 100
26,323.20
(
0.08%
)
Dow Jones
48,809.78
(
-0.68%
)
Brent Oil
110.21
(
5.55%
)
Bitcoin
75,271.98
(
-1.41%
)
News Focus
News Focus
Post# of 257465
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122904
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 211762

Tuesday, 01/02/2018 9:56:46 AM

Tuesday, January 02, 2018 9:56:46 AM

Post# of 257465
INO amends terms of VGX-3100 license in Greater China:

https://finance.yahoo.com/news/inovio-enters-license-collaboration-agreement-130000016.html

The gist of the amendment is that INO’s partner, ApolloBio Corporation, is paying more in up-front cash ($23M vs $15M) but is not buying any INO stock. The Feb 2017 PR for the original agreement is in #msg-128651043.

VGX-3100 is a therapeutic vaccine for HPV-related cancers and precancerous conditions, although the above license is for monotherapy treatment of precancerous conditions only.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today